Research Paper Volume 13, Issue 6 pp 8355—8368
90K predicts the prognosis of glioma patients and enhances tumor lysate-pulsed DC vaccine for immunotherapy of GBM in vitro
Figure 5. Combination of 90K and apoptotic U251 cells improved the performance of DC vaccine. (A) Mature DC under electric microscope. (B) Apoptosis U251-90K-DC group had more cells contact and fusion than other groups (red arrowhead). (C) The expression of CD11c on immature DC, Mature DC, 90K-DC, Apoptosis U251-DC and Apoptosis U251-90K-DC groups.